title: Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study.
abstract: OBJECTIVE
  To examine whether the addition of one dose of preovulatory GnRH agonist could improve implantation and pregnancy rates in GnRH antagonist IVF cycles.
  
  
  METHODS
  Prospective, randomized clinical trial.
  
  
  METHODS
  University-affiliated IVF and infertility unit.
  
  
  METHODS
  Two hundred twenty-one patients intended for GnRH antagonist protocol IVF.
  
  
  METHODS
  Patients were prospectively randomized to two groups. The control group received hCG (5,000 U) 34 hours before oocyte aspiration, and the study group received triptorelin (0.2 mg SC) in addition to hCG. All other treatment parameters were identical.
  
  
  METHODS
  Oocyte pick-up day serum levels of E(2), P, LH, and FSH and implantation and pregnancy rates per started cycle and per completed cycle.
  
  
  RESULTS
  A total of 200 ET cycles were carried out: 97 in the study group and 103 in the control group. None of the cycle parameters of the study or control groups differed, excepting mean oocyte pick-up day FSH (11.26 IU/L [95% confidence interval (CI) 9.88-12.52] vs. 6.27 IU/L [95% CI 5.76-8.77]) and LH levels (5.19 IU/L [95% CI 4.47-5.9] vs. 3.28 IU/L [95% CI 2.22-4.18]). The implantation rate was 19.9% (52 of 261) for the study group and 13.9% (35 of 251) for the control group. The pregnancy rate in completed cycles and the ongoing pregnancy rate per ET were significantly higher in the study group than in the control group: 29.1% (30 of 103) in the control group and 44.3% (43 of 97) in the study group, and 22.3% (23 of 103) and 36.1% (35 of 97), respectively. However, the improvement in pregnancy rate per started cycle did not reach statistical significance (40.9% vs. 28.3%).
  
  
  CONCLUSIONS
  The administration of triptorelin (0.2 mg) at the time of hCG administration in GnRH antagonist IVF cycles significantly improved overall and ongoing pregnancy rates in completed cycles but not in all started cycles. It is possible that this was achieved owing to an endometrial GnRH receptor effect, which should also be examined by direct endometrial studies.
authors.affiliation: IVF and Infertility Unit, Assaf Harofeh Medical Center, Tel Aviv University, Zerifin, Israel. ivfdoc@asaf.health.gov.il
authors.forename: Morey
authors.initials: M
authors.lastname: Schachter
authors.forename: Shevach
authors.initials: S
authors.lastname: Friedler
authors.forename: Raphael
authors.initials: R
authors.lastname: Ron-El
authors.forename: Ariel L
authors.initials: AL
authors.lastname: Zimmerman
authors.forename: Deborah
authors.initials: D
authors.lastname: Strassburger
authors.forename: Orna
authors.initials: O
authors.lastname: Bern
authors.forename: Arieh
authors.initials: A
authors.lastname: Raziel
mesh_terms: D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage*; D005307:Fertilization in Vitro / Q000379:methods / Q000706:statistics & numerical data*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000037:antagonists & inhibitors*; D006801:Humans; D015994:Incidence; D007247:Infertility, Female / Q000453:epidemiology* / Q000628:therapy*; D054315:Oocyte Retrieval / Q000706:statistics & numerical data*; D011247:Pregnancy; D018873:Pregnancy Rate; D011292:Premedication / Q000379:methods / Q000706:statistics & numerical data; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D005300:Fertility Agents, Female; D007987:Gonadotropin-Releasing Hormone